Search Results
Oct 07, 2025, 08:30 ET Overcoming Regulatory Hurdles in AAV Production, Upcoming Webinar Hosted by Xtalks
TORONTO, Oct. 7, 2025 /PRNewswire/ -- As cell and gene therapy (CGT) advances, regulatory expectations around product quality and manufacturing rigor continue to rise, especially in viral vector production,
More news about: Xtalks
Oct 07, 2025, 08:04 ET BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary
Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC. (f/k/a SAVSU Technologies, Inc.) ("SAVSU"), its wholly owned cold chain
More news about: BioLife Solutions, Inc.
Oct 07, 2025, 08:00 ET RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
RheumaGen focuses on editing the human leukocyte antigen (HLA), or "immune gene," to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado, and partners with ClinImmune Cell & Gene Therapy at the University of Colorado Anschutz Medical Campus for clinical
More news about: RheumaGen, Inc.
Oct 07, 2025, 08:00 ET In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I
This is a momentous event for Immusoft and for the broader gene therapy community, which has long sought the ability to re-dose systemically to express therapeutic proteins at high levels. "The vast majority of gene therapies are not re-dosable with current technologies, for a variety of
More news about: Immusoft
Oct 07, 2025, 08:00 ET GEMMABio Launches Rare Therapeutics, Inc. to Develop and Deliver Gene Therapies for Ultra‑Orphan Diseases
living with rare diseases. The company conducts research and product development functions to bring gene therapy discoveries from the bench to the bedside faster and affordably. GEMMABio is led by gene therapy industry pioneer Jim Wilson and his team of experts, who previously conducted their work in
More news about: GEMMA Biotherapeutics
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks
More news about: Equity Insider
Oct 07, 2025, 05:04 ET CURE ALZHEIMER'S FUND AWARDS 1,000TH RESEARCH GRANT
the testing of potential therapies. CureAlz also has established collaborative consortia focused on such critical areas as tau pathology, the APOE gene, the neuroimmune response, the blood-brain barrier, the role of the microbiome and, most recently, brain aging. Together, these innovative initiatives
More news about: Alzheimer's Disease Research Foundation
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
ShenZhen Biotechnology, Artiva Bio, KeyMed Biosciences, IASO, JW Therapeutics, ROME Therapeutics, Ventus Therapeutics, Allosite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, LongBio Pharma, Amytrx Therapeutics, Corestem, Eliem Therapeutics, SinoMab Bioscience Ltd., among others.
More news about: DelveInsight Business Research, LLP
Oct 06, 2025, 11:03 ET Wasatch BioLabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control
Pharmacogenomics (PGx) Panel (RUO)Developed by Oxford Nanopore, the PGxpanel delivers full-gene coverage – including repeats, structural variants, and hybrid alleles that are often missed by short-read methods. By offering the panel as a service,
More news about: Wasatch BioLabs
Oct 06, 2025, 10:23 ET Made Scientific and Streamline Bio Announce Collaboration to Accelerate AI-Driven Robotic Manufacturing for Cell Therapies
development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges in cell and gene therapy (CGT) manufacturing processes, today announced successful initial validation of Streamline Bio's AI-driven precision robotics platform in a
More news about: Made Scientific, Inc.
Oct 06, 2025, 09:00 ET Impilo to Enhance Supply Chain Visibility for Current Health
Current Health is also the country's largest provider of remote technology and services for outpatient and community delivery of complex cell and gene therapies, CAR-T, bispecific immunotherapies, and other emerging treatments, helping to serve patients closer to home while ensuring access to breakthrough
More news about: Impilo
Oct 06, 2025, 09:00 ET American Foundation for Suicide Prevention Announces $8.5 Million Investment in Research Funding for Genetics, Neurobiology, Therapies, Interventions and More
conditions most associated with it. This study, conducted by researcher, Dr. Adolfo Sequeira and colleagues, is the first study to explore suicide specific gene expression changes both in blood and brain tissue in subjects with Major Depressive Disorder (MDD). This study is part of the vision to one day be able
More news about: American Foundation for Suicide Prevention
Oct 06, 2025, 09:00 ET NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
change from baseline, while no significant change was observed in the placebo group over time. MicroRNAs are master regulators of gene expression. The miRNAs described above are associated with neuroinflammation, amyloid and tau pathology, synaptic dysfunction which relate to a cognitive
More news about: NeuroSense
Oct 06, 2025, 08:18 ET Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
Company and encouraging interim results from its Phase 1/2 clinical trial of the investigational gene therapy rAAV-Olig001-ASPA (MYR-101) for Canavan disease at the 2025 Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine (ARM) in Phoenix,
More news about: Myrtelle, Inc
Oct 06, 2025, 08:00 ET Matica Biotechnology Emerges as the Go-To CDMO for Cell & Gene Therapy in 2025
/PRNewswire/ -- Matica Biotechnology, Inc., a U.S.-based Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies (CGT), announced today that it has secured over 10 new manufacturing projects in first half of 2025, surpassing its total 2024 revenue by
More news about: Matica Biotechnology, Inc.
Oct 06, 2025, 07:05 ET REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted Subretinal surabgene lomparvovec on track to be first gene therapy for wet AMD
More news about: REGENXBIO Inc.
Oct 05, 2025, 13:39 ET CHRISTOPHER ECCLESTON APPEARING AT CHICAGO TARDIS FOR 20TH ANNIVERSARY OF DOCTOR WHO RETURN
survey to our attendees each year asking what they want to see the next year. They have been asking for a New Series Doctor for a long time," Showrunner Gene Smith explained. "This was the year that we managed to be able to line things up and get the 9th Doctor just like people have asked."
More news about: Chicago TARDIS
Oct 04, 2025, 10:30 ET Human Papilloma Virus/HPV Test and Pap Smear/Test Market worth US$3.94 billion by 2030 with 10.0% CAGR | MarketsandMarkets™
INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, In. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd. (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain),
More news about: MarketsandMarkets
Oct 03, 2025, 05:58 ET Active Pharmaceutical Ingredients (API) Market to Surpass US$ 428.5 Billion by 2033 as Biotech APIs and Oncology Applications Lead Global Growth | DataM Intelligence
Biotech Boom: Expansion of monoclonal antibodies, gene therapy, and RNA-based therapies is redefining API pipelines. Outsourcing Surge: Global pharma
More news about: DataM Intelligence 4 Market Research LLP
Oct 03, 2025, 02:00 ET The Department of Clinical and Molecular Medicine of Sapienza University of Rome, Takis and Tethis start a collaboration to advance HER3-targeted therapies and diagnostics
developed COVID-eVax, a DNA-based vaccine against SARS-CoV-2, and continues to apply its electroporation expertise to vaccine development and somatic gene therapy. About Tethis Tethis (
More news about: Tethis S.p.A.
Oct 02, 2025, 15:03 ET Student Transportation of America Achieves $100M+ in Growth as Strategic Acquisitions and Market Expansions Accelerate
services. "This period of disciplined growth reflects STA's commitment to strategically expanding our transportation services," said Gene Kowalczewski, CEO of Student Transportation of America. "By growing our reach into new states, securing additional district contracts, and expanding
More news about: Student Transportation of America
Oct 02, 2025, 15:00 ET Frente Parlamentar de Prevenção de Doenças Pulmonares Graves faz projeção no Congresso Nacional para conscientizar sobre doenças respiratórias, como a fibrose pulmonar
gastrointestinal, seios nasais, glândulas sudoríparas e trato reprodutivo. A FC é causada por uma proteína CFTR defeituosa e/ou ausente devido a certas mutações no gene CFTR. As crianças devem herdar dois genes CFTR defeituosos — um de cada pai — para ter FC, e essas mutações podem ser identificadas por meio de um teste
More news about: Boehringer Ingelheim
Oct 02, 2025, 11:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease
those previously unable to reach therapeutic levels in the CNS—to become viable options for treatment of neurological conditions, brain cancers, and gene therapies. Market Impact and Patient Benefits For the approximately
More news about: ExQor Technologies Inc
Oct 02, 2025, 10:58 ET HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer's Disease
with the number projected to rise to around 50 million by 2050. Genetic factors account for 60-80% of the risk for late-onset AD, with the APOE gene being the most extensively studied, followed by TREM2. Both genetic risk factors exhibit significant differences in prevalence and risk effects
More news about: The Hong Kong University of Science and Technology
Oct 02, 2025, 10:39 ET HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer's Disease
with the number projected to rise to around 50 million by 2050. Genetic factors account for 60-80% of the risk for late-onset AD, with the APOE gene being the most extensively studied, followed by TREM2. Both genetic risk factors exhibit significant differences in prevalence and risk effects
More news about: The Hong Kong University of Science and Technology